Atorvastatin is a unique hypolipidemic drug. Atorvastatin can: Decrease both LDL and triglycerides together without adverse effects, increases HDL levels as well. Atorvastatin decreases formation of cholesterol by inhibiting 3-Hydroxy-3-Methyl Glutaryl Coenzyme A reductase (HMG CoA reductase).

Inhibition of synthesis of cholesterol leads to increased formation of LDL receptors. Thus LDL is cleared from the blood.

VLDL can also bind to LDL receptor and thus gets cleared from blood. Atorvastatin reduces the LDL level by 35-61%, Triglycerides - 10-45%, Total cholesterol - 17-46% and Increases HDL level by 3-12%.

Mixed dyslipidemia
Hypercholesterolemia

10 - 80 mg/day can be safely given.
Most patients reach target lipid levels with 10-20 mg OD.

Atorvastatin is contraindicated in patients who are hypersensitive to atorvastatin or having liver disease.

The drug is generally well tolerated. Rarely it shows the elevation of transaminase level, abdominal pain, myalgia, diarrhoea and fatigue.

Atorin is available as a strip of 10 tablets.

Atorin-EZ is the novel fixed dose combination of atorvastatin (an HMG-COA reductase inhibitor) and ezetimibe, first once-daily potent and selective inhibitor of cholesterol absorption.

Atorin-EZ is the promising and effective combination with Dual mechanism of action i.e. inhibition of cholesterol synthesis and absorption and thus causes more impressive cholesterol decreasing effect.

Atorin-EZ avoids the "escape phenomenon" associated with long-term statin therapy. Ezetimibe in Atorin-EZ offers better control of LDL-cholesterol as compared to statins alone and helps in achieving NCEP-goals.

Atorin-EZ less likely to produce dose related side effects such as muscle toxicity. Thus, Atorin-EZ is the double-edged sword to fight the dreadful cardiovascular events, which are the major health problem across the world.

• It is indicated as an adjunctive therapy with diet for reduction of Total-C, LDL-C and APO-B in-patients with Primary hypercholesterolemia.
• High risk dyslipidemic patients not achieving their LDL-C goals with monotherapy
• Dyslipidemic patients not able to tolerate high dose of statins

One tablet once daily.

Hypersensitivity to ezetimibe/ atorvastatin
Liver disease
Pregnant and nursing women

The drug is generally well tolerated. Rarely it shows the elevation of transaminase level, abdominal pain, myalgia, diarrhoea and fatigue.

Atorin-EZ is available as a strip of 10 tablets.

Atorin-F is the novel fixed dose combination of atorvastatin an 3-Hydroxy, 3-Methyl Glutaryl Coenzyme A Reductase inhibitor and Fenofibrate. Fenofibric acid, the active metabolite of fenofibrate produces reduction in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients.

In addition, treatment with fenofibrate results in increase in high-density lipoprotein (HDL) and apoproteins.

Diabetic dyslipidemia
Dyslipidemic patients not able to tolerate high dose of statins
Primary hypercholesterolaemia

One tablet once daily.

Hypersensitivity to Fenofibrate/ Atorvastatin
Liver disease
Pregnant and nursing women

Drug is generally well tolerated. Rarely does it show elevation of transaminase level, abdominal pain, myalgia, diarrhoea and fatigue. It is recommended that patient on therapy should check serum transaminases every three months.

Atorin-F is available as a strip of 10 tablets.